Relatively few patients in the CARRA JIA Registry with SJIA were treated with ETN, likely because ETN is less effective in SJIA [17], is not FDA approved for SJIA, and anti-TNF agents have been replaced by FDA approved therapies targeting IL-1 or IL-6 in this category of JIA [18, 19]. This evidence concerns the gene IL6 and systemic-onset juvenile idiopathic arthritis.